title: Delineation of the molecular mechanisms of nucleoside recognition by cytidine deaminase through virtual screening.
abstract: Cytidine deaminase (EC 3.5.4.5, CDA), an enzyme of the pyrimidine salvage pathways, is responsible for the degradation and inactivation of several cytidine-based antitumor drugs such as cytarabine, gemcitabine, decitabine, and azacytidine. Thus, CDA inhibitors are highly sought after as compounds to be co-administered with said drugs to improve their effectiveness. Alternatively, the design of antitumor drugs not susceptible to the action of CDA is also regarded as an attractive solution. Herein we describe a virtual screen for CDA ligands based on chemical similarity and molecular docking. The campaign led to the identification of three novel inhibitors and one novel substrate, with a 19 % hit rate, and allowed a significant extension of the structure-activity relationships, also in light of the compounds that resulted inactive. The most active compound identified through the screen is the inhibitor pseudoisocytidine, which has the potential to serve as a lead for highly stable compounds. The study also delineated the detrimental effect of 5-aza and 6-aza substitutions, the incompatibility of the presence of an amino group at the 3'-position, as well as the presence of very strict steric requirements around the 2'-arabino position and, even more, the N4-position. Importantly, these features can be exploited for the design of novel anti-neoplastic agents resistant to the action of CDA.
authors: Laboratory of Biological Modeling, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, DHHS, 12A South Drive, Bethesda, MD 20892, USA. stefanoc@mail.nih.gov
authors: Stefano
authors: S
authors: Costanzi
authors: Santiago
authors: S
authors: Vilar
authors: Daniela
authors: D
authors: Micozzi
authors: Francesco M
authors: FM
authors: Carpi
authors: Giulio
authors: G
authors: Ferino
authors: Alberto
authors: A
authors: Vita
authors: Silvia
authors: S
authors: Vincenzetti
references: J Chem Inf Comput Sci. 2002 Nov-Dec;42(6):1273-80
references: 12444722
references: Arch Biochem Biophys. 1991 Nov 1;290(2):285-92
references: 1929398
references: J Mol Graph Model. 2006 Sep;25(1):10-6
references: 16303324
references: Int J Biol Macromol. 2010 Nov 1;47(4):471-82
references: 20637228
references: Protein Eng. 1998 Jan;11(1):59-63
references: 9579661
references: Protein Expr Purif. 1996 Sep;8(2):247-53
references: 8812871
references: J Comput Aided Mol Des. 2010 Jun;24(6-7):591-604
references: 20354892
references: Cancer Res. 1976 Apr;36(4):1520-3
references: 1260769
references: Protein Eng. 2003 Dec;16(12):1055-61
references: 14983087
references: J Med Chem. 2005 Feb 10;48(3):658-60
references: 15689149
references: Cancer Res. 1980 Nov;40(11):4243-9
references: 7471064
references: Cancer Chemother Pharmacol. 2011 Feb;67(2):421-30
references: 20443002
references: Cancer Chemother Pharmacol. 2009 Feb;63(3):411-6
references: 18398609
references: Biochemistry. 2006 Jun 27;45(25):7825-33
references: 16784234
references: J Comput Aided Mol Des. 2007 Dec;21(12):681-91
references: 17899391